Loading company…
LWBP develops medicines for oncology, autoimmune diseases, tumor immunotherapy, and viral infections.
Founded in 2012 and based in Shanghai, LWBP develops medicines for unmet clinical needs. Its lead product, LW231, is a hepatitis B drug candidate in Phase Ib/II clinical trials. In October 2025, it raised Series B funding from Xiamen C&D Group, Wuxi Huading Capital, Qiming Venture Partners, Chuchang Fund, and Shanghai STVC Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in